-
Understand the competition of green leaf product line! What does its future depend on?
Time of Update: 2018-01-24
LVYE pharmaceutical focuses on the largest and fastest-growing treatment fields in tumor, cardiovascular system, digestion and metabolism, central nervous system and other markets Its business has cov
-
Innovation Medicine burst out! Is Sansheng pharmaceutical expected to gain more profits?
Time of Update: 2018-01-23
Wonderful content recently, Sansheng pharmaceutical announced that baidayang ® was officially approved by CFDA and became the first long-acting GLP-1 receptor agonist approved in China for the treatme
-
Late stage market of influenza and severe cold, anti herpesvirus drugs are in danger
Time of Update: 2018-01-22
Among the antiviral drugs, broad-spectrum antiviral drugs developed rapidly at the end of the 20th century The rapid growth of the number of antiviral drugs and the amount of antiviral drugs has objec
-
The first generic drug that broke through in 2017
Time of Update: 2018-01-20
In recent years, the state has issued a series of policies, including encouraging drug innovation, priority evaluation, drug listing license holder system, generic drug consistency evaluation, etc., w
-
Looking at the status of anti-tumor drug declarations in 2017, 2 monoclonal antibodies and 3 tinibs are worth looking forward to!
Time of Update: 2018-01-18
Antitumor drugs have always been a hot area for innovative companies to explore, and also the main force for national priority review and approval policies According to the drug intelligence registration and acceptance database, of the 4810 records accepted by CDE in 2017, 163 were included in the priority review, 30 of which were anti-tumor drugs, and its development naturally attracted the attention of people in the industry So in 2017, how about the declaration of domestic antineoplastic drugs?
-
Looking at the 10-year new drug registration and approval, we will further explore the R & D layout of 2017 enterprises, including dongyangguang, Hengrui, Qilu and Kangyuan
Time of Update: 2018-01-15
2017 has passed, and we have a new year in 2018 Looking back yesterday, the pharmaceutical industry has gone through a year that is not easy but also has its own harvest The author has carefully prepa
-
Paramiway up 174%! Domestic oseltamivir to expand its leading advantages
Time of Update: 2018-01-14
According to the information released by the National Influenza Center, at present, influenza activities in the north and south of China are at the level of epidemic season, and are still on the rise
-
In this winter, the market of respiratory chemicals reached 50 billion yuan, and the share of antiallergic drugs soared
Time of Update: 2018-01-14
Since the winter of 2017, the North has been dry with little snow and the South has been cold and humid, which has led to an increase in the number of people with allergic reactions, and the number of
-
Holding 11 over 100 million products, six new products will be added to the R & D acceleration of Lizhu group
Time of Update: 2018-01-07
On December 23, 2017, Lizhu group issued a notice that dantraline sodium for injection, which had been included in the priority review earlier, was approved by CFDA for clinical application; on Decemb
-
The first batch of consistency evaluation varieties are the most comprehensive analysis! Market scale, competition pattern, future trend
Time of Update: 2018-01-02
The era of oligopoly is coming So, what are the current market patterns of the first 12 varieties that have passed the consistency evaluation? How do they stir up the market competition pattern and im
-
The 12 first batch of products that passed the consistency evaluation, 8 sales exceeded one billion, and more than 50 acceptance numbers are on the way to review...
Time of Update: 2018-01-02
On December 29, CFDA released the first batch of drugs that passed the consistency evaluation of quality and efficacy of generic drugs After statistics, minenet found that this batch of drugs involved
-
"China class 1" new drugs approved for market in recent years (biological medicine)
Time of Update: 2018-01-02
Innovative drug research and development is the only way for China to move from a big pharmaceutical country to a powerful pharmaceutical country Whether it is the "863 Plan", "973 Plan" or today's "N
-
Analysis of China's market of lipid-lowering drugs from 2013 to 2016
Time of Update: 2017-12-28
Wonderful content according to the 2016 edition of China's guidelines for the prevention and treatment of adult dyslipidemia, China's cardiovascular events will increase by about 9.2 million in 2010-2
-
Analysis of the current situation of domestic listed drugs, short board and opportunities are here!
Time of Update: 2017-12-28
According to the database of drug intelligence drug screening system, there are 169816 drugs on the domestic market (calculated by approval number, the same below), including 165774 domestic drugs, 40
-
The research and development costs of these 8 domestically produced new drugs have exceeded 100 million yuan
Time of Update: 2017-12-27
For a long time, the pharmaceutical industry has a "double decade" for R & D investment in new drugs, that is, it will take at least ten years and one billion dollars In fact, it's almost 10 years old
-
Reform Dongfeng Zhengsheng, 2017 new drug R & D market
Time of Update: 2017-12-26
2017 is coming to an end, and I'm feeling that this year is really going by so fast Some pharmaceutical companies have quietly applied for several class 1 new drugs, some of them are old giants and so
-
Priority evaluation and favorable evaluation: Top 3 of the most beneficial domestic pharmaceutical companies, with a closer look at the performance of key varieties after listing
Time of Update: 2017-12-26
Since the first batch of priority review varieties at the beginning of 2016, 25 batches of priority review catalogue have been issued, involving nearly 391 acceptance numbers The latest batch of publi
-
Lizhu, Hengrui, Beida Nine innovative drugs have a great future! Who can enter the catalogue of Chinese listed chemicals?
Time of Update: 2017-12-24
Highlights Recently, CDE released the first batch of varieties included in the catalogue of chemical drugs on the market in China, and solicited opinions from the public This time, 119 products and 18
-
In 2017, the number of class 1 new drug applications may exceed 200!
Time of Update: 2017-12-21
According to CPM database of China Pharmaceutical Industry Information Center, as of December 20, 2017, CDE has undertaken 199 class 1 chemicals, an increase of 42% over 2016 It is true that "explosiv
-
87 original drugs delisting countdown! How can generic drugs seize the market through consistency evaluation?
Time of Update: 2017-12-21
The industry shuffle period brought by consistency evaluation is coming According to the report of Tianfeng Securities Research Institute, as of December 6, a total of 63 batches were in the CDE consi
